Endocrine Abstracts

Introduction: Recent advances in energy homeostasis revealed a significant interconnection between bone and adipose tissue through osteocalcin. Reduced bone mass documented in type 1 diabetes mellitus (T1D) could be related to disregulation of adipokine signaling on bone.Materials and Methods: We evaluated 40 children and adolescents with T1D (mean±S.D. age 13.04±3.53 years, mean±S.D. T1D duration 5.15±3....

Introduction: T1DM is a risk factor for reduced bone mass, disrupting several bone metabolic pathways. Dickkopf-1 is an inhibitor of the Wnt/b-catenin bone metabolic pathway. Increased fracture risk and elevated Dickkopf-1 levels have been documented in adult patients with T2DM. No relevant data exist on childhood T1DM. Our aim was to study plasma Dickkopf-1 concentration in children and adolescents with T1DM and controls and to correlate Dickkopf-1 levels with metabolic bone ...

Introduction: Sclerostin is an inhibitor of the Wnt/β-catenin bone metabolic pathway. Increased sclerostin levels and reduced bone mineral density (BMD) have been documented in adult patients with diabetes mellitus (DM), predominantly in those with type 2 diabetes mellitus (T2DM). No relevant data exist on childhood T1DM. Our aim was to study plasma sclerostin concentration in children and adolescents with T1DM and controls and to correlate sclerostin levels with metaboli...

Introduction: Diabetes mellitus (DM) is a risk factor for reduced bone mass. Several bone metabolic pathways seem to be disrupted in patients with type 1 diabetes mellitus (T1DM).Materials and methods: We evaluated 40 children and adolescents with T1DM (mean±S.D., age 13.04±3.53 years, mean±S.D., T1DM duration 5.15±3.33 years) and 40 healthy age- and gender-matched controls (mean±S.D.,...